SM
AKBA icon

Sabby Management’s Akebia Therapeutics AKBA Stock Holding History

Sabby Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-102,338
Closed -$975K – 141
2018
Q1 		$975K Buy
+102,338
New +$1.43M 0.12% 65

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sabby Management's AKBA Position: Q2 2018 in Review

Sabby Management sold out of Akebia Therapeutics (AKBA) in Q2 2018, closing a stake of 102,338 shares — an estimated $975K sold.

Sabby Management first reported a position in AKBA in Q1 2018 and held it in 1 quarter. The position peaked at $975K in Q1 2018. 145 funds tracked by Wall St. Rank hold AKBA as of Q2 2018.

  • Sabby Management reported no remaining Akebia Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Sabby Management sold 102,338 Akebia Therapeutics shares in Q2 2018, an estimated $975K.
  • Sabby Management first reported a position in Akebia Therapeutics in Q1 2018 and held it in 1 quarter.
  • Sabby Management's Akebia Therapeutics position peaked at $975K in Q1 2018.
  • 145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.